Geneva, Switzerland

Peter R Statkov

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 1985.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:

goldMedal1 out of 834,453 
Other
 patents

Years Active: 1985

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Peter R Statkov

Introduction

Peter R Statkov is a notable inventor based in Geneva, Switzerland. He has made significant contributions to the field of pharmacology through his innovative work. His research focuses on the development of therapeutic compounds that have the potential to improve health outcomes.

Latest Patents

Peter R Statkov holds a patent for "Derivatives of p-acylaminophenol having a therapeutic action, and new acyl derivatives of p-aminophenol and esters of the same useful as pharmacologically active ingredients and process for their preparation." This patent highlights his commitment to advancing medical science and providing new solutions for therapeutic applications. He has 1 patent to his name.

Career Highlights

Throughout his career, Statkov has demonstrated a strong dedication to research and innovation. His work has been instrumental in the development of new pharmacological agents that can be used in various therapeutic contexts. His expertise in the field has earned him recognition among his peers.

Collaborations

Peter R Statkov has collaborated with several professionals in his field, including Francois Molnar and Suzanne Szabo. These collaborations have allowed him to expand his research and contribute to the advancement of pharmacological science.

Conclusion

Peter R Statkov is a distinguished inventor whose work in pharmacology has the potential to impact the medical field significantly. His innovative patents and collaborations reflect his commitment to improving health through scientific research.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…